logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. Long-term depot medroxyprogesterone acetate (Depo-Provera) use in inner-city adolescents.

    Article - En anglais

    Purpose 

    To determine Depo-Provera continuation rates and reasons for its discontinuation among adolescents.

    Study Design 

    Medical record reviews and telephone interviews with 159 adolescents who initiated Depo-Provera use between 1 December 1992 and 31 December 1995 at two clinics in New York City.

    Depo-Provera continuation was measured using lifetable analysis.

    Results 

    The mean age was 17.7 ± 1.5 years, with a median of 1 pregnancy (range 0-11).

    Mean follow-up was 23.4 ± 10.7 months.

    Depo-Provera continuation rates were 71% at 3 months, 48% at 6 months, and 27% at 12 months, and were not affected by age, race, pregnancy or contraceptive history, clinic, or foster care status.

    Forty-three subjects (37% of discontinuers) restarted Depo-Provera during the study period, with a mean time to restart of 8.4 months after the last Depo-Provera injection.

    Side effects were the main reported reason for Depo-Provera discontinuation, primarily menstrual irregularities (26%) and weight gain (18%). Seventy percent of those discontinuing Depo-Provera owing to irregular bleeding did so after only one injection.

    For 23%, the single reason for discontinuation was appointment noncompliance.

    Restart rates were lowest among those who reported irregular bleeding (15%), weight gain (9%), and hair loss (10%), and highest among those discontinuing owing to missed appointments (87%) (p<0.05).

    Pregnancies occurred in 19% of Depo-Provera discontinuers. (...)

    Mots-clés Pascal : Prévention, Gestation, Contraception, Médroxyprogestérone, Contraceptif, Forme libération contrôlée, Observance thérapeutique, Long terme, Adolescent, Homme, Femelle

    Mots-clés Pascal anglais : Prevention, Pregnancy, Contraception, Medroxyprogesterone, Contraceptive, Controlled release form, Treatment compliance, Long term, Adolescent, Human, Female

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 98-0450005

    Code Inist : 002B20A01. Création : 25/01/1999.